Following after Forxiga, Jardiance is also preparing to introduce the heart failure indication in South Korea.

According to a pharmaceutical industry insider, Boehringer Ingelheim Korea is waiting for the health authority’s review result in its sodium-glucose cotransporter 2 (SGLT-2) inhibitor Jardiance’ request to expand indication in treating adult patients with heart failure with reduced ejection fraction (HFrEF) regardless of diabetic status. The South Korean authority has approved the same indication in competing Forxiga (dapagliflozin) in last December.

The U.S. Food and Drug Administration (FDA) has reportedly granted a fast-track status on Jardiance’ indication, which is als